Pharmacoeconomic evaluation of carfilzomib versus ixazomib for the treatment of relapsed and refractory multiple myeloma

Pharmacoeconomic evaluation of carfilzomib versus ixazomib for the treatment of relapsed and refractory multiple myeloma

Objective This study assesses the cost-effectiveness of carfilzomib plus lenalidomide and dexamethasone (KRd) versus ixazomib plus lenalidomide and dexamethasone for relapsed and refractory multiple myeloma (RRMM) in China.Methods A survival model was used to analyze health states and costs over a l...

Full description

Saved in:
Bibliographic Details
Main Authors: Lin Wang, Fen Chen, Yuanyuan Ma, Xihan Lin, Jinyu Liu, Yu Zhang, Ruxu You
Format: Article
Language:English
Published: Taylor & Francis Group 2025-12-01
Series:Future Science OA
Subjects:
Carfilzomib
ixazomib
cost-effectiveness
multiple myeloma
meta-analysis
Online Access:https://www.tandfonline.com/doi/10.1080/20565623.2025.2514969
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.tandfonline.com/doi/10.1080/20565623.2025.2514969

Similar Items